Become a Fan and "Like" us on FB

Monday, January 27, 2014


Regenerative Medicine by definition is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function. It is my opinion that regenerative medicine is the future of medicine and it is just a matter of time before it becomes the new standard of care. The growth opportunity for companies that can show efficacy in this field is comparable to Microsoft's (MSFT) introduction of Windows and Apple (AAPL) selling the iPhone. It is my belief that regenerative medical therapy is at its beginning stages and this new innovative technology will evolve into mainstream medical care.
Advancements in the field of regenerative medicine by a wide variety of companies have shown results which can potentially lead to unbelievable market potential. Because of this, large pharmaceuticals are beginning to realize the significance of regenerative medicine and the implications it can have on the industry. While there is competition in the industry, it is my belief that Athersys, Inc. (ATHX) is the frontrunner because of its patents, technology, advancing clinical studies, and pipeline. I believe this confirmed, in part, by the fact that Pfizer (PFE) chose to partner with Athersys over the competition.
The two most studied adult stem cells are derived from bone marrow and they are: Mesenchymal stem cells (MSCs) and Multipotent adult progenitor cells (MAPCs). Athersys uses MAPCs in their MultiStem platform. In 2009, an indepth study performed in China compared the therapeutic potential of both cell types. The results of the study was published in Advanced Studies in Biology in 2009. The findings were that "MSCs gradually lost its multiple differentiation potential and phenotype with the increase of passages, whereas MAPCs well retained pluripotency. Therefore, MAPCs may hold a greater promise in the future of clinical application than MSCs." What does this mean for Athersys and their competition?

No comments: